We use cookies for a better user experience. Read our Privacy Policy

I Agree

Liposome Drug Delivery Market

Liposome Drug Delivery Market (Product: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, and Others; Technology: Stealth Liposome Technology, Non-PEGylated Liposome Technology, and DepoFoam Liposome Technology; and Application: Fungal Diseases, Pain Management, Cancer Therapy, Viral Vaccines, and Photodynamic Therapy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Special Nanomaterials and Liposomes Hold Potential as Antiviral Agents against Coronavirus

The COVID-19 (coronavirus) has exposed the vulnerabilities of healthcare facilities. Due to the increasing number of COVID-19 patients, especially in the U.S. and European countries, research institutes are pressurized to accelerate their R&D activities to develop drugs and vaccines for the treatment of coronavirus. Thus, companies in the liposome drug delivery market are capitalizing on this opportunity to increase their research in nanomaterials such as nanospheres, liposomes, and nanoparticles that are effective antiviral agents. Liposome drug delivery is being leveraged with increased in vivo and in vitro drug activities for routine clinical practices.

Companies in the liposome drug delivery market are increasing their focus on drug delivery nanosystems involving major antiviral classes and their transport across specific barriers at cellular and intracellular levels. Thus, liposomes hold promising potentials in ongoing research studies being carried out by healthcare companies for the treatment of coronavirus.

liposome drug delivery market infographic

To know the scope of our report Get a Sample on Liposome Drug Delivery Market 

Liposome Drug Delivery Transitions from Conventional Vesicles to Second Generation Liposomes

New strategies in surface modification of liposomes are generating incremental opportunities for pharmaceutical companies. The liposome drug delivery is being highly publicized as a useful biocompatible tool for the vehiculation and delivery of lipophilic, hydrophilic, and ampiphilic compounds. However, high toxicity and resistance in high doses are some of the limitations faced by companies in the liposome drug delivery market. Hence, companies are transitioning from simple conventional vesicles to second-generation liposomes by attuning the lipid composition and surface with different ligands.

Get a glimpse of the in-depth analysis through our Report Brochure

Companies are focusing on surface chemistry of the liposome technology. Increased research in liposome technology are contributing toward a robust CAGR of ~9% for the liposome drug delivery market. PEGylated liposomes are gaining popularity for possessing higher drug loading capacity. Novel drugs such as the CPX-1 encapsulated in liposomes are beneficial for increased disease control in patients suffering from colorectal cancer. As such, the revenue of cancer therapy application segment is projected for aggressive growth during the forecast period.

New Lipid Compositions Optimize Stability and Drug Vehiculization Capabilities of Liposomes

Liposomes are gaining widespread acceptance as Nano-carriers for diverse pharmaceutical applications. Compositions of phospholipids and cholesterol are becoming increasingly useful in liposome drug delivery. On the other hand, nanotechnology is optimizing liposome drug delivery. Hence, pharmaceutical companies are exploring alternative compositions with cholesterol and new techniques such as nanotechnology to enhance the stability and drug release profiles. They are using liposomes to its full potential for the generation of extracellular vesicles by targeted cells.

Companies in the liposome drug delivery market are increasing their R&D activities to unlock new lipid compositions and strategies that optimize the stability and drug vehiculization capabilities of liposomes. Such experiments are instrumental for innovative liposome fabrication. This explains why the liposome drug delivery market is expected to experience favorable Y-o-Y growth, owing to an estimated revenue of ~US$ 8 Bn by the end of 2027. Thus, innovative designs in liposomal architectures are proving beneficial for improved in vivo and in vitro drug activities.

Liposomes Gain Popularity for Enhancing Circulation Time of Hydrophobic Substances

Therapeutic efficacy of PEGylated liposomal Doxorubicin is being leveraged with improved liposomal formulations of galbanic acid (Gba) in the liposome drug delivery market. Galbanic acid is a sesquiterpene coumarin possessing strong antiangiogenic activity, resulting in promising potential as an anti-cancer agent. However, galbanic acid poses limitations in water solubility, thus hampering its clinical applications. Hence, companies in the market for liposome drug delivery are increasing the applicability of PEGylated liposomal Gba produced through the thin film hydration plus extrusion method to overcome limitations of poor Gba solubility.

Present chemotherapeutic agents in cancer chemotherapy are accompanied with several side effects. Hence, companies in the liposome drug delivery market are increasing their efficacy in PEGylated liposomal Gba to minimize side effects in patients. As such, liposomes are acquiring popularity to enhance circulation time and reduce the systemic toxicity of hydrophobic substances such as Gba to leverage their therapeutic efficacy for drugs in the market of liposome drug delivery.

liposome drug delivery market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report 

Analysts’ Viewpoint

Liposomes are being highly publicized as potential antiviral agents instrumental in reducing social impact and economic burden caused due to the COVID-19 outbreak. Companies in the liposome drug delivery market are gaining expertise in the formulation of advanced liposomes possessing greater solubility and long circulating time to improve drug release profiles.

Surface chemistry of liposome technology has enabled liposomes to be further liganded with vitamins, carbohydrates, and peptides, among others. However, maintaining physical properties of liposomal formulations poses as a challenge for market players. Hence, companies should refer the NRC’s (National Research Council) certified reference material program to comply with industry standards and maintain physical characteristics of liposomal formulations.

Liposome Drug Delivery Market: Overview

  • The global liposome drug delivery market was valued at US$ 3.6 Bn in 2018 and is projected to expand at a considerable CAGR from 2019 to 2027. Liposomes are considered the novel drug delivery systems, which are defined as vesicular structures consisting of bilayers formed spontaneously when phospholipids are dispersed in water. Liposomes aid in delivering drugs by the process of diffusion rather than by direct cell fusion.
  • The global liposome drug delivery market is driven by rise in prevalence of cancer, which is primarily treated with liposome encapsulated drugs, increase in applications of liposomes as drug delivery systems, its advantages, technological advances, and strong pipeline of drugs
  • Advantages offered by liposome drug delivery, including the unique ability to entrap both hydrophilic and lipophilic compounds and enabling a diverse range of drugs to be encapsulated by these vesicles, contribute to the growth of the global market
  • Applications of liposomes in drug delivery can be segregated into diagnostic and therapeutic. These applications include anti-fungal, anti-cancer, and anti-inflammatory drugs, in addition to therapeutic gene delivery. Major drugs formulated by employing liposome drug delivery include Doxil, AmBisome, and DepoDur. Surge in applications of liposomes as drug delivery systems contributes to the growth of the global liposome drug delivery market.

Liposome Drug Delivery Market: Segmentation

  • The global liposome drug delivery market has been segmented based on product, technology, application, and region
  • In terms of product, the global liposome drug delivery market has been categorized into liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others
  • Based on technology, the global liposome drug delivery market has been classified into stealth liposome technology, non-PEGylated liposome technology, and DepoFoam liposome technology
  • In terms of application, the global liposome drug delivery market has been divided into fungal diseases, cancer therapy, viral vaccines, pain management, and photodynamic therapy. The cancer therapy segment dominated the market in 2018 and the trend is anticipated to continue during the forecast period. This can be attributed to rise in prevalence of cancer and strong pipeline of drugs focused on offering treatment for various types of cancer.

Liposome Drug Delivery Market: Regional Segmentation

  • In terms of region, the global liposome drug delivery market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
  • North America dominated the global liposome drug delivery market in 2018 and the trend is expected to continue during the forecast period
  • The liposome drug delivery market in Asia Pacific is anticipated to expand at a high CAGR from 2019 to 2027. Growth of the market in the region can be attributed to increase in number of patients suffering from chronic diseases and focus of leading players on strengthening presence in emerging markets.

Liposome Drug Delivery Market: Major Players

  • Key players operating in the global liposome drug delivery market are 
    • Spectrum Pharmaceuticals, Inc.
    • Astellas Pharma, Inc.
    • Gilead Sciences, Inc.
    • Celsion Corporation
    • Ipsen Pharma
    • Pacira BioSciences, Inc.
    • Luye Pharma Group
    • Novartis AG
    • Takeda Pharmaceutical Company Limited
    • Johnson & Johnson
  • These players focus on adopting inorganic growth strategies and product launches to strengthen their product portfolio. These players also emphasize on enhancement of technological platforms for the development of liposome drugs. For instance, Celsion Corporation focuses on the development of cancer therapies based on its Lysolipid Thermally Sensitive Liposomes (LTSL), which is a heat-sensitive liposomal formulation. The other technology platforms include TheraPlas, a non-viral delivery system for therapeutic plasmids. The third technology platform is TheraSilence, which aids in delivering synthetically generated inhibitory RNA (RNAi) to regulate protein expression in target cells.

Liposome Drug Delivery Market – Segmentation

Product

Liposomal Doxorubicin

Liposomal Paclitaxel

Liposomal Amphotericin B

Others

Technology

Stealth Liposome Technology

Non-PEGylated Liposome Technology

DepoFoam Liposome Technology

Application

Fungal Diseases

Cancer Therapy

Pain Management

Viral Vaccines

Photodynamic Therapy

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Frequently Asked Questions

How big was the global liposome drug delivery market in 2018?

Liposome drug delivery market was valued at US$ 3.6 Bn in 2018

What is the total market worth of liposome drug delivery market?

Liposome drug delivery market to reach valuation of ~US$ 8 Bn by 2027

What are the key driving factors for the growth of the liposome drug delivery market?

Liposome drug delivery market is driven by increase in therapeutic and diagnostic applications

Which region is expected to project the highest market share in the global liposome drug delivery market?

North America accounted for a major share of the global liposome drug delivery market and the trend is expected to continue during the forecast period

Who are the key players in the liposome drug delivery market?

Key players in the global liposome drug delivery market include Spectrum Pharmaceuticals, Inc., Astellas Pharma, Inc., Gilead Sciences, Inc., Celsion Corporation, Ipsen Pharma

     1. Preface

         1.1. Market Definition and Scope

         1.2. Market Segmentation

         1.3. Key Research Objectives

         1.4. Research Highlights

     2. Assumptions and Acronyms

     3. Research Methodology

     4. Executive Summary: Global Liposome Drug Delivery Market

     5. Market Overview

         5.1. Definition

         5.2. Market Indicators

         5.3. Market Dynamics

             5.3.1. Drivers

             5.3.2. Restraints

             5.3.3. Opportunities

         5.4. Global Liposome Drug Delivery Market Revenue (US$ Mn) Forecast 2017–2027

         5.5. Global Liposome Drug Delivery Market Outlook

     6. Key Insights

         6.1. Pipeline Analysis

         6.2. Clinically Marketed Liposome Drugs

         6.3. Regulatory Scenario Assessment

     7. Global Liposome Drug Delivery Market Analysis and Forecast, by Product 

         7.1. Introduction 

         7.2. Global Liposome Drug Delivery Market Value Share Analysis, by Product

         7.3. Global Liposome Drug Delivery Market Value Forecast, by Product, 2017–2027

             7.3.1. Liposomal Doxorubicin

             7.3.2. Liposomal Paclitaxel

             7.3.3. Liposomal Amphotericin B

             7.3.4. Others

         7.4.  Global Liposome Drug Delivery Market Attractiveness Analysis, by Product 

     8. Global Liposome Drug Delivery Market Analysis and Forecast, by Technology

         8.1. Introduction 

         8.2. Global Liposome Drug Delivery Market Value Share Analysis, by Technology

         8.3. Global Liposome Drug Delivery Market Value Forecast, by Technology, 2017–2027

             8.3.1. Stealth Liposome Technology

             8.3.2. Non-PEGylated Liposome Technology

             8.3.3. DepoFoam Liposome Technology

         8.4. Global Liposome Drug Delivery Market Attractiveness Analysis, by Technology

     9. Global Liposome Drug Delivery Market Analysis and Forecast, by Application

         9.1. Introduction 

         9.2. Global Liposome Drug Delivery Market Value Share Analysis, by Application

         9.3. Global Liposome Drug Delivery Market Value Forecast, by Technology, 2017–2027

             9.3.1. Fungal Diseases

             9.3.2. Pain Management

             9.3.3. Cancer Therapy

             9.3.4. Viral Vaccines

             9.3.5. Photodynamic Therapy

         9.4. Global Liposome Drug Delivery Market Attractiveness Analysis, by Technology

     10. Global Liposome Drug Delivery Market Analysis and Forecast, by Region 

         10.1. Regional Outlook

         10.2. Introduction

         10.3. Global Liposome Drug Delivery Market Value Forecast, by Region

             10.3.1. North America

             10.3.2. Europe 

             10.3.3. Asia Pacific

             10.3.4. Latin America 

             10.3.5. Middle East & Africa

         10.4. Global Liposome Drug Delivery Market Attractiveness Analysis, by Region

     11. North America Liposome Drug Delivery Market Analysis and Forecast

         11.1.  Key Findings

         11.2.  North America Liposome Drug Delivery Market Value Forecast, by Product, 2017–2027

             11.2.1. Liposomal Doxorubicin

             11.2.2. Liposomal Paclitaxel

             11.2.3. Liposomal Amphotericin B

             11.2.4. Others 

         11.3. North America Liposome Drug Delivery Market Value Forecast, by Technology, 2017–2027

             11.3.1. Stealth Liposome Technology

             11.3.2. Non-PEGylated Liposome Technology

             11.3.3. DepoFoam Liposome Technology

         11.4. North America Liposome Drug Delivery Market Value Forecast, by Application, 2017–2027

             11.4.1. Fungal Diseases

             11.4.2. Pain Management

             11.4.3. Cancer Therapy

             11.4.4. Viral Vaccines

             11.4.5. Photodynamic Therapy

         11.5. North America Liposome Drug Delivery Market Value Forecast, by Country, 2017–2027

             11.5.1. U.S.

             11.5.2. Canada

         11.6. North America Liposome Drug Delivery Market Attractiveness Analysis

             11.6.1. By Product

             11.6.2. By Technology

             11.6.3. By Application

             11.6.4. By Country

     12. Europe Liposome Drug Delivery Market Analysis and Forecast

         12.1.  Key Findings

         12.2.  Europe Liposome Drug Delivery Market Value Forecast, by Product, 2017–2027

             12.2.1. Liposomal Doxorubicin

             12.2.2. Liposomal Paclitaxel

             12.2.3. Liposomal Amphotericin B

             12.2.4. Others 

         12.3. Europe Liposome Drug Delivery Market Value Forecast, by Technology, 2017–2027

             12.3.1. Stealth Liposome Technology

             12.3.2. Non-PEGylated Liposome Technology

             12.3.3. DepoFoam Liposome Technology

         12.4. Europe Liposome Drug Delivery Market Value Forecast, by Application, 2017–2027

             12.4.1. Fungal Diseases

             12.4.2. Pain Management

             12.4.3. Cancer Therapy

             12.4.4. Viral Vaccines

             12.4.5. Photodynamic Therapy

         12.5. Europe Liposome Drug Delivery Market Value Forecast, by Country/Sub-region, 2017–2027

             12.5.1. U.K.

             12.5.2. Germany

             12.5.3. France

             12.5.4. Italy 

             12.5.5. Spain

             12.5.6. Rest of Europe

         12.6. Europe Liposome Drug Delivery Market Attractiveness Analysis

             12.6.1. By Product

             12.6.2. By Technology

             12.6.3. By Application

             12.6.4. By Country/Sub-region

     13. Asia Pacific Liposome Drug Delivery Market Analysis and Forecast

         13.1.  Key Findings

         13.2.  Asia Pacific Liposome Drug Delivery Market Value Forecast, by Product, 2017–2027

             13.2.1. Liposomal Doxorubicin

             13.2.2. Liposomal Paclitaxel

             13.2.3. Liposomal Amphotericin B

             13.2.4. Others 

         13.3. Asia Pacific Liposome Drug Delivery Market Value Forecast, by Technology, 2017–2027

             13.3.1. Stealth Liposome Technology

             13.3.2. Non-PEGylated Liposome Technology

             13.3.3. DepoFoam Liposome Technology

         13.4. Asia Pacific Liposome Drug Delivery Market Value Forecast, by Application, 2017–2027

             13.4.1. Fungal Diseases

             13.4.2. Pain Management

             13.4.3. Cancer Therapy

             13.4.4. Viral Vaccines

             13.4.5. Photodynamic Therapy

         13.5. Asia Pacific Liposome Drug Delivery Market Value Forecast, by Country/Sub-region, 2017–2027

             13.5.1. China

             13.5.2. India

             13.5.3. Japan

             13.5.4. Australia & New Zealand 

             13.5.5. Rest of Asia Pacific 

         13.6. Asia Pacific Liposome Drug Delivery Market Attractiveness Analysis

             13.6.1. By Product

             13.6.2. By Technology

             13.6.3. By Application

             13.6.4. By Country/Sub-region

     14. Latin America Liposome Drug Delivery Market Analysis and Forecast

         14.1.  Key Findings

         14.2.  Latin America Liposome Drug Delivery Market Value Forecast, by Product, 2017–2027

             14.2.1. Liposomal Doxorubicin

             14.2.2. Liposomal Paclitaxel

             14.2.3. Liposomal Amphotericin B

             14.2.4. Others 

         14.3. Latin America Liposome Drug Delivery Market Value Forecast, by Technology, 2017–2027

             14.3.1. Stealth Liposome Technology

             14.3.2. Non-PEGylated Liposome Technology

             14.3.3. DepoFoam Liposome Technology

         14.4. Latin America Liposome Drug Delivery Market Value Forecast, by Application, 2017–2027

             14.4.1. Fungal Diseases

             14.4.2. Pain Management

             14.4.3. Cancer Therapy

             14.4.4. Viral Vaccines

             14.4.5. Photodynamic Therapy

         14.5. Latin America Liposome Drug Delivery Market Value Forecast, by Country/Sub-region, 2017–2027

             14.5.1. Brazil

             14.5.2. Mexico

             14.5.3. Rest of Latin America 

         14.6. Latin America Liposome Drug Delivery Market Attractiveness Analysis

             14.6.1. By Product

             14.6.2. By Technology

             14.6.3. By Application

             14.6.4. By Country/Sub-region

     15. Middle East & Africa Liposome Drug Delivery Market Analysis and Forecast

         15.1.  Key Findings

         15.2.  Middle East & Africa Liposome Drug Delivery Market Value Forecast, by Product, 2017–2027

             15.2.1. Liposomal Doxorubicin

             15.2.2. Liposomal Paclitaxel

             15.2.3. Liposomal Amphotericin B

             15.2.4. Others 

         15.3. Middle East & Africa Liposome Drug Delivery Market Value Forecast, by Technology, 2017–2027

             15.3.1. Stealth Liposome Technology

             15.3.2. Non-PEGylated Liposome Technology

             15.3.3. DepoFoam Liposome Technology

         15.4. Middle East & Africa Liposome Drug Delivery Market Value Forecast, by Application, 2017–2027

             15.4.1. Fungal Diseases

             15.4.2. Pain Management

             15.4.3. Cancer Therapy

             15.4.4. Viral Vaccines

             15.4.5. Photodynamic Therapy

         15.5. Middle East & Africa Liposome Drug Delivery Market Value Forecast, by Country/Sub-region, 2017–2027

             15.5.1. GCC Countries

             15.5.2. South Africa

             15.5.3. Rest of Middle East & Africa 

         15.6. Middle East & Africa Liposome Drug Delivery Market Attractiveness Analysis

             15.6.1. By Product

             15.6.2. By Technology

             15.6.3. By Application

             15.6.4. By Country/Sub-region

     16. Competition Landscape

         16.1.  Company Profiles

             16.1.1. Spectrum Pharmaceuticals, Inc. 

                 16.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                 16.1.1.2. Financial Overview

                 16.1.1.3. Product Portfolio

                 16.1.1.4. Strategic Overview

                 16.1.1.5. SWOT Analysis

             16.1.2. Astellas Pharma Inc. 

                 16.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                 16.1.2.2. Financial Overview

                 16.1.2.3. Product Portfolio

                 16.1.2.4. Strategic Overview

                 16.1.2.5. SWOT Analysis

             16.1.3. Gilead Sciences, Inc. 

                 16.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                 16.1.3.2. Financial Overview

                 16.1.3.3. Product Portfolio

                 16.1.3.4. Strategic Overview

                 16.1.3.5. SWOT Analysis

             16.1.4. Celsion Corporation

                 16.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                 16.1.4.2. Financial Overview

                 16.1.4.3. Product Portfolio

                 16.1.4.4. Strategic Overview

                 16.1.4.5. SWOT Analysis

             16.1.5. Ipsen Pharma

                 16.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                 16.1.5.2. Financial Overview

                 16.1.5.3. Product Portfolio

                 16.1.5.4. Strategic Overview

                 16.1.5.5. SWOT Analysis

             16.1.6. Pacira BioSciences, Inc.

                 16.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                 16.1.6.2. Financial Overview

                 16.1.6.3. Product Portfolio

                 16.1.6.4. Strategic Overview

                 16.1.6.5. SWOT Analysis

             16.1.7. Luye Pharma Group

                 16.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                 16.1.7.2. Financial Overview

                 16.1.7.3. Product Portfolio

                 16.1.7.4. Strategic Overview

                 16.1.7.5. SWOT Analysis

             16.1.8. Novartis AG

                 16.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                 16.1.8.2. Financial Overview

                 16.1.8.3. Product Portfolio

                 16.1.8.4. Strategic Overview

                 16.1.8.5. SWOT Analysis

             16.1.9. Takeda Pharmaceutical Company Limited

                 16.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                 16.1.9.2. Financial Overview

                 16.1.9.3. Product Portfolio

                 16.1.9.4. Strategic Overview

                 16.1.9.5. SWOT Analysis

             16.1.10. Johnson & Johnson

                 16.1.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                 16.1.10.2. Financial Overview

                 16.1.10.3. Product Portfolio

                 16.1.10.4. Strategic Overview

                 16.1.10.5. SWOT Analysis

    List of Tables

    Table 01: Pipeline Analysis - Liposome Drug Delivery Systems

    Table 02: Clinically Marketed Liposome Drugs

    Table 03: Regulations - Principle difference between U.S., EU, and India 

    Table 04: Regulatory Scenario Assessment - Administrative Requirements 

    Table 05: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017–2027

    Table 06: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017–2027

    Table 07: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017–2027

    Table 08: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Region, 2017–2027

    Table 09: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 10: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017–2027

    Table 11: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017–2027

    Table 12: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017–2027

    Table 13: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 14: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017–2027

    Table 15: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017–2027

    Table 16: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017–2027

    Table 17: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 18: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017–2027

    Table 19: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017–2027

    Table 20: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017–2027

    Table 21: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 22: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017–2027

    Table 23: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017–2027

    Table 24: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017–2027

    Table 25: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 26: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017–2027

    Table 27: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017–2027

    Table 28: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017–2027 

    List of Figures

    Figure 01: Global Liposome Drug Delivery Market Snapshot

    Figure 02: Global Liposome Drug Delivery Market Value (US$ Mn), by Region, 2018 and 2027

    Figure 03: Therapeutic applications of liposomes in drug delivery 

    Figure 04: Advantages of Liposome Drug Delivery System

    Figure 05: Global Liposome Drug Delivery Market Value (US$ Mn) and Y-o-Y (%) Forecast, 2017–2027

    Figure 06: Global Liposome Drug Delivery Market Value Share, by Product, 2019

    Figure 07: Global Liposome Drug Delivery Market Value Share, by Technology, 2019

    Figure 08: Global Liposome Drug Delivery Market Value Share, by Application, 2019

    Figure 09: Global Liposome Drug Delivery Market Value Share, by Region, 2019

    Figure 10: Regulatory Approval Process - U.S.

    Figure 11: Regulatory Approval Process - Europe

    Figure 12: Regulatory Approval Process - India

    Figure 13: Global Liposome Drug Delivery Market Value Share Analysis, by Product, 2018 and 2027

    Figure 14: Global Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2019–2027

    Figure 15: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Liposomal Doxorubicin, 2017–2027

    Figure 16: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Liposomal Paclitaxel, 2017–2027

    Figure 17: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Liposomal Amphotericin B, 2017–2027

    Figure 18: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027

    Figure 19: Global Liposome Drug Delivery Market Value Share Analysis, by Technology, 2018 and 2027

    Figure 20: Global Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2019–2027

    Figure 21: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Stealth Liposome Technology, 2017–2027

    Figure 22: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Non-PEGylated Liposome Technology, 2017–2027

    Figure 23: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by DepoFoam Liposome Technology, 2017–2027

    Figure 24: Global Liposome Drug Delivery Market Value Share Analysis, by Application, 2018 and 2027

    Figure 25: Global Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2019–2027

    Figure 26: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Fungal Diseases, 2017–2027

    Figure 27: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Pain Management, 2017–2027

    Figure 28: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cancer Therapy, 2017–2027

    Figure 29: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Viral Vaccines, 2017–2027

    Figure 30: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Photodynamic Therapy, 2017–2027

    Figure 31: Liposome Drug Delivery Market – Regional Outlook

    Figure 32: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, 2017–2027

    Figure 33: Global Liposome Drug Delivery Market Value Share Analysis, by Region, 2018 and 2027

    Figure 34: Global Liposome Drug Delivery Market Attractiveness Analysis, by Region, 2019–2027

    Figure 35: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 36: North America Liposome Drug Delivery Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 37: North America Liposome Drug Delivery Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

    Figure 38: North America Liposome Drug Delivery Market Value Share Analysis, by Product, 2018 and 2027

    Figure 39: North America Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2019–2027

    Figure 40: North America Liposome Drug Delivery Market Value Share Analysis, by Technology, 2018 and 2027

    Figure 41: North America Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2019–2027

    Figure 42: North America Liposome Drug Delivery Market Value Share Analysis, by Application, 2018 and 2027

    Figure 43: North America Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2019–2027

    Figure 44: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 45: Europe Liposome Drug Delivery Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 46: Europe Liposome Drug Delivery Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

    Figure 47: Europe Liposome Drug Delivery Market Value Share Analysis, by Product, 2018 and 2027

    Figure 48: Europe Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2019–2027

    Figure 49: Europe Liposome Drug Delivery Market Value Share Analysis, by Technology, 2018 and 2027

    Figure 50: Europe Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2019–2027

    Figure 51: Europe Liposome Drug Delivery Market Value Share Analysis, by Application, 2018 and 2027

    Figure 52: Europe Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2019–2027

    Figure 53: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 54: Asia Pacific Liposome Drug Delivery Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 55: Asia Pacific Liposome Drug Delivery Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

    Figure 56: Asia Pacific Liposome Drug Delivery Market Value Share Analysis, by Product, 2018 and 2027

    Figure 57: Asia Pacific Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2019–2027

    Figure 58: Asia Pacific Liposome Drug Delivery Market Value Share Analysis, by Technology, 2018 and 2027

    Figure 59: Asia Pacific Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2019–2027

    Figure 60: Asia Pacific Liposome Drug Delivery Market Value Share Analysis, by Application, 2018 and 2027

    Figure 61: Asia Pacific Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2019–2027

    Figure 62: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 63: Latin America Liposome Drug Delivery Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 64: Latin America Liposome Drug Delivery Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

    Figure 65: Latin America Liposome Drug Delivery Market Value Share Analysis, by Product, 2018 and 2027

    Figure 66: Latin America Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2019–2027

    Figure 67: Latin America Liposome Drug Delivery Market Value Share Analysis, by Technology, 2018 and 2027

    Figure 68: Latin America Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2019–2027

    Figure 69: Latin America Liposome Drug Delivery Market Value Share Analysis, by Application, 2018 and 2027

    Figure 70: Latin America Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2019–2027

    Figure 71: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 72: Middle East & Africa Liposome Drug Delivery Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 73: Middle East & Africa Liposome Drug Delivery Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

    Figure 74: Middle East & Africa Liposome Drug Delivery Market Value Share Analysis, by Product, 2018 and 2027

    Figure 75: Middle East & Africa Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2019–2027

    Figure 76: Middle East & Africa Liposome Drug Delivery Market Value Share Analysis, by Technology, 2018 and 2027

    Figure 77: Middle East & Africa Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2019–2027

    Figure 78: Middle East & Africa Liposome Drug Delivery Market Value Share Analysis, by Application, 2018 and 2027

    Figure 79: Middle East & Africa Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2019–2027 

Copyright © Transparency Market Research, Inc. All Rights reserved